• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Limited prognostic value of interim PET/CT during B-cell lymphoma treatment

byMonica ParksandDavid Wang
July 19, 2015
in Chronic Disease, Imaging and Intervention, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a prospective cohort study of 138 patients undergoing the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for diffuse large B-cell lymphoma (DLBCL), patients with interim negative PET/CT scans did not demonstrate a greater event free survival compared to patients with interim positive PET/CT scans.

Evidence Rating Level: 2 (Good)   

Study Rundown: The current chemotherapy regimen for patients with DLBCL is R-CHOP. Current cure rates with R-CHOP are variable, ranging from 30-70%. Previous studies have demonstrated that PET/CT scans have a high sensitivity for detecting sites of DLBCL and end-of-treatment PET/CT scans have a high predictive value for overall survival. However, the prognostic value of PET/CT during the R-CHOP cycle is unclear. The purpose of this prospective cohort study of patients undergoing R-CHOP was to assess the prognostic value of interim PET/CT in this population. This was a prospective trial of 138 patients with DLBCL who underwent PET/CT scan after two cycles of R-CHOP. At the conclusion of the trial, having a negative interim PET/CT scan was significantly associated with an increase in 2-year event free survival compared to patients with positive PET/CT scans. However, there was no difference in the overall survival between the positive and negative interim PET/CT scan groups. The results of the study support the conclusion that interim PET/CT scans have limited prognostic value for patients with DLBCL treated with R-CHOP and are not sufficiently accurate to be used to guide treatment decisions. The strength of the study is the large, multi-centered study design. However, the study is limited by a short period of follow-up (2 years), which may not be sufficient to detect changes in overall survival.

Click to read the study in JCO

Relevant Reading: Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy

In-Depth [prospective cohort]: This study was a multicenter, prospective, single-arm study that enrolled a total of 138 patients with DLBCL who were scheduled to undergo standard R-CHOP therapy (6 cycles of R-CHOP followed by two cycles of rituximab). PET/CT scans were performed in all patients at the time of diagnosis, after the first two chemotherapy cycles, and at the end of treatment. Those with progressive disease at interim PET/CT had no further scans, while those with positive scans at 2 cycles had a repeat scan after 4 cycles. No treatment decisions were made by the results of these scans unless progressive disease was seen. The primary end point was event-free survival at 2 years (2-year EFS), with events defined as disease progression, death, or initiation of non-protocol cancer treatment or radiotherapy. Secondary endpoint included two-year overall survival. Of the initial 138 patients, 129 completed the initial, 2-cycle, and end of treatment scans. At the conclusion of the trial, patients with PET-positive interim scans had significant decreased 2-year EFS compared to patients with PET-negative scans (48.2%; 95% CI: 33.1-58.4 vs. 74.2%; 95% CI: 60.3-83.8; p = 0.002). There was no difference in overall survival at 2 years for those with positive or negative results after 2 cycles (87.7% vs. 90.6%, p = 0.6).

Image: CC/Blausen

RELATED REPORTS

Addition of fludrocortisone to hydrocortisone is beneficial in management of septic shock

Surveillance testing of staff at nursing facilities reduces resident COVID-19 mortality

Childhood maltreatment may cause mental health problems

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Syndecan-4 identified as novel target for asthma treatment [PreClinical]

Next Post

Antibiotic misconceptions persist in Medicaid-insured parents

RelatedReports

Obstetric scoring systems overestimate cases of severe sepsis
Emergency

Addition of fludrocortisone to hydrocortisone is beneficial in management of septic shock

March 31, 2023
Age may not impact residential status after abdominal surgery
Infectious Disease

Surveillance testing of staff at nursing facilities reduces resident COVID-19 mortality

March 31, 2023
Multiple factors may increase risk of falls in young children
Pediatrics

Childhood maltreatment may cause mental health problems

March 31, 2023
#VisualAbstract: Hydrochlorothiazide does not impact risk of kidney-stone recurrence
StudyGraphics

#VisualAbstract: Hydrochlorothiazide does not impact risk of kidney-stone recurrence

March 31, 2023
Next Post
Antibiotic misconceptions persist in Medicaid-insured parents

Antibiotic misconceptions persist in Medicaid-insured parents

Rate of weight loss may not affect long-term weight control

Frequent, low-dose weight loss strategy effective in children

Choosing Wisely campaign releases recommendations in newborn medicine

Choosing Wisely campaign releases recommendations in newborn medicine

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Addition of fludrocortisone to hydrocortisone is beneficial in management of septic shock
  • Surveillance testing of staff at nursing facilities reduces resident COVID-19 mortality
  • Childhood maltreatment may cause mental health problems
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options